• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Roche - Articles and news items

roche-skin-cancer-not-effective

NICE says Roche’s skin cancer drug not cost effective

Industry news / 6 September 2016 / Niamh Louise Marriott, Digital Content Producer

The committee agreed the combination offers life extending benefit compared to vemurafenib alone, however compared to alternative treatments it is too expensive. About 1,000 people would have been eligible each year…

study-roche

Roche’s cancer immunotherapy drug has longer OS vs. chemotherapy

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events were consistent with what has […]

Gazyvaro Roche

Blood cancer study yields disappointing results

Industry news / 19 July 2016 / Niamh Louise Marriott

Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma…

Ocrevus

Ocrevus marketing applications under review by the EMA and FDA

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

If approved by the EMA and FDA for both indications, Ocrevus would be the first and only treatment for both forms of multiple sclerosis…

Takeda & Seattle Genetics announce positive data from trial for cutaneous T-cell lymphoma 

EC approves Gazyvaro plus bendamustine in follicular lymphoma

Industry news / 16 June 2016 / Victoria White, Digital Content Producer

The EC has approved Gazyvaro in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma…

Tecentriq

Tecentriq to dominate the bladder cancer market, says GlobalData

Industry news / 14 June 2016 / Victoria White, Digital Content Producer

The launch of Roche’s Tecentriq will usher in a dramatic change in the treatment paradigm of bladder cancer, according to an analyst with GlobalData…

avastin

EC approves Avastin plus Tarceva in NSCLC

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The combination is approved for the first-line treatment of adult patients with non-squamous NSCLC with EGFR-activating mutations…

mabthera

EC approves MabThera for chronic lymphocytic leukaemia

Industry news / 31 May 2016 /

The EC has approved the subcutaneous formulation of MabThera for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia…

gazyva

Positive results from Phase III study of Gazyva in follicular lymphoma

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

Results from an interim analysis showed that Gazyva-based treatment significantly reduced the risk of disease worsening or death…

lariam

Lariam only to be considered as a last resort, says Defence Committee

Industry news / 24 May 2016 / Victoria White, Digital Content Producer

Lariam, the anti-malarial drug sometimes prescribed to British troops, should be considered only as a drug of last resort, says the Defence Committee…

lung cancer

Study reveals Alecensa is effective against specific type of lung cancer in Japanese patients

Industry news / 20 May 2016 / Katie Sadler

Roche has announced that Alecensa, an oral anaplastic lymphoma kinase (ALK) inhibitor, reduced the risk of disease worsening or death in Japanese people with advanced or recurrent, ALK-positive non-small cell lung cancer (NSCLC).

atezolizumab

FDA grants priority review for Roche’s atezolizumab in NSCLC

Industry news / 11 April 2016 / Victoria White, Digital Content Producer

The FDA has granted a priority review for atezolizumab for the treatment of locally advanced or metastatic NSCLC that expresses the protein PD-L1…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +